Cancer detection method
AssigneesExonhit Therapeutics SA, Biomerieux
InventorsAlexander Krause, Philippe Leissner, Malick Paye, Bruno Mougin, Fabien Schweighoffer, Laurent Bracco
Life of this patent
Estimating the term…
Loading patent…
AssigneesExonhit Therapeutics SA, Biomerieux
InventorsAlexander Krause, Philippe Leissner, Malick Paye, Bruno Mougin, Fabien Schweighoffer, Laurent Bracco
Estimating the term…
The present application concerns methods and compositions which can be used to detect cancer in mammals, in particular in humans. It notably describes serum markers of cancers and their uses in diagnosis methods. It also concerns tools and/or kits which can be used to implement these methods (reagents, probes, primers, antibodies, chips, cells, etc.), their preparation and their uses. The invention can be used to detect the presence or the progression of a cancer, particularly breast cancer, including at an early stage.
Method to detect the presence or risk of developing a cancer in a mammal, comprising the detection, in a biological sample of the mammal:
Method for in vitro or ex vivo detection of the presence or risk of developing a cancer in a mammal, comprising the determination of the presence (or absence) in a biological sample of the mammal, preferably a blood (derived) sample), of an alteration in a gene or RNA involved in the stimulation of TLRs, in the secretion of cytokins, or in the activation of T lymphocytes, said gene or RNA advantageously being chosen from among receptors, adapters, enzymes, factors involved in the regulation of gene expression, chemokins, cytokins and interleukins, the presence of said alteration being indicative of the presence or risk of developing a cancer in this mammal.
Method according to any of the preceding claims, comprising the detection of the presence or absence of a nucleic acid by selective hybridization or selective amplification.
Method according to any of the preceding claims, characterized in that the sample is a blood derived sample, preferably a sample of whole blood.
Method according to any of the preceding claims, to detect the presence of an early stage breast cancer of stage I or II.
Product comprising a carrier on which at least two separate nucleic acid probes are immobilized, comprising a sequence complementary to and/or specific to at least two separate target nucleic acids containing at least two sequences chosen from among SEQ ID NO:
Dependencies are inferred from the claim text.